Sell Gerovital H3 100％ Original Ready Stock best price

Gerovital H3 100％ Original 1Box 5vials x 5ml Gerovital is promoted with false claims[according to whom?] of its curative abilities for a wide range of human ailments; research has found no evidence that it has any health benefit[citation needed][the claim that research has found no evidence that it has any health benefit -- is not backed by any citation of a study or review. In fact, there are studies that show evidence for a benefit - albeit not for the dubious purpose of 'anti-aging' which is itself a straw-man of an absurd type.] or "anti-aging"[citation needed] [who is making that claim other than a single article cited over and over again from 2013?] properties.[1] [Addendum: It is of the opinion of this editor it is not a coincidence that the actual studies are simply not even mentioned. The actual evidence shows that GH3 as a reversible monoamine oxidase inhibitor i.e. it increases the availability of neurotransmitters such as serotonin and dopamine, together with lowering cortisol, is a potential treatment for anxiety, depression, which can, in turn, improve outcome, thus might, in fact, have "any health benefit" as our sycophants for the war on drugs are all too quick to allege. We see in one study in 2015 that: "Participants were men and women between 50 and 89 years of age, with a median of 62.53 years. Before the intervention, the demographic characteristics and the baseline SF-36 scores, low mood, and anxiety statuses were comparable (p > 0.05). After the 12-week intervention, the scores of role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), mental health (MH) and health transition (HT), mental composite score (MCS) of the G.H.3. group were higher than the placebo group (p < 0.05), There were no significant differences in other domains in SF-36 and PCS between the two groups(p > 0.05), the scores of SDS and SAS in the G.H.3. group were both lower than the placebo group(p < 0.01), the prevalence rates of low moods in the G.H.3. group and the placebo group were 20.8 % and 34.0 % respectively, no significant difference was found (χ2 =2.127,p = 0.145), while the prevalence rate of clinical anxiety concerns in the G.H.3. group was 2.1 %, which was significantly lower than the placebo group, 22.0 % (χ2 =9.040,p < 0.001)." [2]]